4,456 Intuitive Surgical, Inc. $ISRG Shares Sold by Fifth Third Wealth Advisors LLC

Key Points

• Fifth Third Wealth Advisors reduced its Intuitive Surgical stake by 28.1%, selling 4,456 shares and retaining 11,395 shares valued at approximately $4.63 million. Institutional investors still own 83.64% of ISRG.
• Intuitive Surgical reported strong third-quarter results, with revenue up 21.7% year over year to $3.05 billion and EPS of $3.00, beating analysts’ estimates. The stock has a consensus “Moderate Buy” rating and an average price target of $493.54.
• Despite solid growth, investors remain concerned about slowing U.S. da Vinci procedure growth, margin pressure from pricing and a roughly $450 million antitrust settlement, and ISRG’s elevated valuation of about 54.7 times earnings.

Fifth Third Wealth Advisors LLC cut its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 28.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,395 shares of the medical equipment provider's stock after selling 4,456 shares during the quarter. Fifth Third Wealth Advisors LLC's holdings in Intuitive Surgical were worth $4,634,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of ISRG. Plato Investment Management Ltd bought a new stake in shares of Intuitive Surgical during the 2nd quarter valued at $4,315,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Intuitive Surgical in the 2nd quarter worth $14,316,000. Hikari Power Ltd bought a new stake in shares of Intuitive Surgical in the 2nd quarter worth about $5,619,000. Nykredit A S bought a new stake in shares of Intuitive Surgical in the 2nd quarter worth about $48,464,000. Finally, NewEdge Advisors LLC raised its position in shares of Intuitive Surgical by 19.1% during the 2nd quarter. NewEdge Advisors LLC now owns 50,825 shares of the medical equipment provider's stock valued at $20,212,000 after buying an additional 8,142 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ISRG has been the subject of several recent research reports. Erste Group Bank upgraded Intuitive Surgical from a "hold" rating to a "buy" rating in a research report on Wednesday. UBS Group reaffirmed a "buy" rating on shares of Intuitive Surgical in a research note on Tuesday, October 13th. BMO Capital Markets reissued an "outperform" rating on shares of Intuitive Surgical in a research report on Monday, July 20th. Truist Financial decreased their price target on Intuitive Surgical from $580.00 to $510.00 and set a "buy" rating on the stock in a report on Thursday, July 16th. Finally, Evercore set a $430.00 price target on Intuitive Surgical in a research report on Monday, July 6th. Twenty-three investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $493.54.

Insider Activity

In related news, VP Fredrik Widman sold 1,089 shares of the business's stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $374.44, for a total transaction of $407,765.16. Following the completion of the transaction, the vice president owned 1,026 shares in the company, valued at $384,175.44. The trade was a 51.49% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Mark Brosius sold 77 shares of the company's stock in a transaction on Friday, August 21st. The shares were sold at an average price of $375.57, for a total value of $28,918.89. Following the completion of the transaction, the executive vice president directly owned 881 shares in the company, valued at $330,877.17. This trade represents a 8.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 12,370 shares of company stock worth $4,891,989 in the last three months. Corporate insiders own 0.60% of the company's stock.

Trending Headlines about Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Intuitive Surgical reported third-quarter revenue of approximately $3.05 billion, up more than 20% year over year, while earnings exceeded consensus expectations. The company also highlighted continued international expansion and adoption of its robotic-surgery systems. Intuitive Surgical Stock: Margin Hit Masks Strong Q3 Growth Story
• Positive Sentiment: Several firms remain constructive: BTIG, Stifel Nicolaus, Piper Sandler, and Oppenheimer reaffirmed or maintained Buy ratings. Baird also raised its price target, while Erste Group upgraded the stock to Buy. ISRG was added to the Zacks Rank #1 Strong Buy list. New Strong Buy Stocks for October 23rd
• Neutral Sentiment: The quarter included roughly $450 million of costs tied to an antitrust settlement, along with pricing-related pressure, which reduced margins. These items appear largely nonrecurring, but investors are assessing their effect on near-term profitability. Intuitive Surgical Reports Q3 2026 Earnings Impacted by $450M Antitrust Settlement
• Negative Sentiment: The key concern is that U.S. da Vinci procedure growth slowed to its lowest level since the COVID period. Investors worry that decelerating domestic demand could make it harder for Intuitive Surgical to sustain its premium valuation, which remains above 50 times earnings. Intuitive Surgical Sinks as U.S. da Vinci Growth Slows
• Negative Sentiment: RBC lowered its expectations for ISRG, and an analyst downgrade contributed to a gap lower in the shares. The market is emphasizing forward growth and valuation rather than the headline earnings beat. Intuitive Surgical Shares Gap Down Following Analyst Downgrade

Intuitive Surgical Price Performance

Shares of NASDAQ ISRG opened at $452.29 on Friday. The company has a market cap of $156.78 billion, a P/E ratio of 54.69, a PEG ratio of 3.31 and a beta of 1.46. Intuitive Surgical, Inc. has a 1 year low of $328.57 and a 1 year high of $603.88. The firm has a 50-day simple moving average of $395.50 and a two-hundred day simple moving average of $409.13.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.35. The business had revenue of $3.05 billion during the quarter, compared to analyst estimates of $2.91 billion. Intuitive Surgical had a return on equity of 18.17% and a net margin of 25.54%. The company's revenue for the quarter was up 21.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.40 earnings per share. As a group, equities research analysts expect that Intuitive Surgical, Inc. will post 8.87 EPS for the current year.

About Intuitive Surgical

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company's primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.